Prostate Cancer SPORE Research Team
Sarki Abdulkadir, MD, PhD
Dr. Abdulkadir is the John T. Grayhack, MD Professor in Urological Research and Professor in Urology at Northwestern University Feinberg School of Medicine. He directs an active research program in the molecular mechanisms of prostate cancer development, advanced animal models, and novel targeted therapeutics. Dr. Abdulkadir collaborates with Drs. Catalona, Stadler, Yu and Vander Griend in the SPORE.
Faculty Profile: http://fsmweb.northwestern.edu/faculty/facultyProfile.cfm?xid=29021
Charles Brendler, MD
Dr. Brendler is Chair of Prostate Cancer at NorthShore University Health System and University of Chicago. He has spent his thirty-five year career in urology helping care for men with prostate cancer and participating in both clinical and translational research devoted to developing improved treatments for this disease.
His research interests focus on active surveillance and developing genetic and metabolic biomarkers that will distinguish indolent from aggressive prostate cancer. NorthShore currently has the largest active surveillance clinical trial in the Midwest with over 200 men enrolled. Dr. Brendler is also interested in the metabolic factors underlying the relationship between obesity and prostate cancer risk and progression. He collaborates with William Catalona, MD, Brian Helfand, MD, PhD, Chung Lee, PhD, Karen Kaul, MD, PhD, Daniel Shevrin, MD and Susan Crawford, MD.
Clinical Profile: http://www.northshore.org/apps/findadoctor/doctor.aspx?docid=5929
Irina Budunova, MD, PhD
Dr. Budunova is an Associate Professor at the Departments of Dermatology/ Urology. Her research interests include the role of the glucocorticoid receptor in prostate tumorigenesis, cross-talk between the glucocorticoid and androgen receptors, and glucocorticoid receptor and pro-inflammatory factor NF-kB. She is also involved in the search of novel non-steroidal modulators of GR and AR. Dr. Budunova is a recipient DOD Prostate cancer research program awards, and SPORE in Prostate Cancer pilot project awards for her work aimed to identify novel FDA-approved small molecules that act as dual modulators of the GR and AR. Dr. Budunova closely collaborates with SPORE team members Olga Volpert, PhD, Ximing Yang, MD, Paul Lindholm, MD and Raymond Bergan, MD.
Faculty Profile : http://www.biology.northwestern.edu/igp/faculty/budunova/
David Cella, PhD
Dr. Cella is Professor and founding Chair of the Department of Medical Social Sciences (MSS) at Northwestern University's (NU) Feinberg School of Medicine. Dr. Cella is also Associate Director for Cancer Prevention and Control at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. Cella has a leading role in the NIH Roadmap Initiative to build a Patient Reported Outcome Measurement Information System (PROMIS), which is now in its second cycle of funding. Dr. Cella has served as the principal investigator of the PROMIS statistical coordinating center and heads the PROMIS steering committee. Dr. Cella collaborates with Dr. Rudy Lombard in the SPORE.
Faculty Profile: http://www.mss.northwestern.edu/faculty/cella.html
Suzanne Conzen, MD
Dr. Conzen is Professor in the Department of Medicine at the University of Chicago. She attended Yale University School of Medicine and completed residency training at New York Hospital-Cornell Medical Center in New York. After fellowship training at both Dartmouth-Hitchcock Medical Center in New Hampshire and the University of Chicago, Dr. Conzen joined the UC faculty. Her clinical focus is on the treatment of patients with breast cancer while her laboratory uses both molecular approaches and animal models to study nuclear receptor biology contributing to the development and progression of human prostate, ovarian and breast cancers. Dr. Conzen collaborates with SPORE investigators Drs. Walter Stadler, Geoffrey Greene, Ramana Davuluri, Borko Jovanovic, Donald Vander Griend and Russell Szmulewitz. She was awarded a 2014 Challenge grant from the Prostate Cancer Foundation to develop glucocorticoid receptor antagonists for treatment of prostate cancer in collaboration with Drs. Szmulewitz, Stadler and Greene.
Faculty Profile: https://biomedsciences.uchicago.edu/page/suzanne-conzen-md
Ramana Davuluri, PhD
Dr. Davuluri is Professor in the Feinberg School of Medicine and Director of Cancer Informatics for the Robert H. Lurie Comprehensive Cancer Center. Dr. Davuluri is also co-director of the Biostatistics & Bioinformatics Core of the SPORE. He has worked in the areas of bioinformatics and computational genomics since 1998 and has directed several nationally funded projects over the past 16 years. He has been awarded three NIH R01s and American Cancer Society Research Scholar Grant to study epigenetic modifications across alternative promoters and associated isoform-level gene signatures in normal and cancer genomes. His research currently focuses on developing data-mining algorithms and informatics solutions for problems in biology and medicine. The overarching goal of the lab is to translate data from high dimensional (-omic) platforms (e.g., NextGen sequencing) to derive experimentally interpretable and testable discovery models towards genomics-based clinical decision support systems. His group is developing bioassays that can rapidly identify biomarkers from human tissue and blood samples. Dr. Davuluri interacts with Drs. Catalona, Szmulewitz and Conzen within the SPORE.
Faculty Profile: http://fsmweb.northwestern.edu/faculty/FacultyProfile.cfm?xid=29607
John F. Downes
Mr. Downes is a prostate cancer survivor. As an advocate for four years, he has attended and supported the Northwestern University SPORE Group. He participates in several Us TOO Chapters and support groups, attended seminars and other prostate cancer related meetings and continues to make efforts to collaborate with our group and others to make a positive difference in the lives of prostate cancer patients.
Geoffrey L. Greene, Ph.D
Dr. Greene is the Virginia and D. K. Ludwig Professor and Vice Chair of the Ben May Department for Cancer Research at the University of Chicago. He is also Co-Director of the Ludwig Center for Metastasis Research. Dr. Greene is known for his work on the function of female hormones and SERMs in breast cancer, and for the development of estrogen and progesterone receptor antibodies, which have had major diagnostic applications in breast cancer throughout the world. The overall objective of his research is to determine the molecular distinctions between estrogen/androgen agonism and antagonism in hormone dependent tissues and cancers and to use this information to identify, develop and characterize novel compounds that can be used for hormone replacement therapy and as breast/prostate cancer chemopreventatives and chemotherapeutics. He is currently collaborating with David Hosfield to develop novel small molecule inhibitors of ATAD2 that can be used for prostate cancer therapy. He also collaborates with Ralph Weichselbaum on a project to develop radiolabeled androgens for internal prostate cancer radiotherapy.
Faculty profile: http://benmay.uchicago.edu/faculty/greene
Ludwig Center: http://ludwigcenter.sites.uchicago.edu
Michael Gurley is a Systems Analyst/Programmer with the Northwestern Biomedical Informatics Center (NUBIC). Michael is the software developer responsible for developing the clinical and specimen inventory databases of the SPORE in Prostate Cancer. He is a programmer with 15 years experience across the entire software development life cycle. He has developed a novel approach to integrating curated data with data directly extracted from Northwestern Medicineâ€™s electronic medical record systems. He has also developed a system to ease the workflow of requesting, approving and disbursing requests for specimens and/or clinical data from the Northwestern SPORE in Prostate Cancer.
Irene Helenowski, PhD
Dr. Helenowski is a statistical analyst for the SPORE in Prostate Cancer and a Biostatistician for the Department of Surgery in the Feinberg School of Medicine. Dr. Helenowski provides statistical guidance to SPORE project leaders under the guidance of Dr. Borko Jovanovic. She is working closely with Jennifer Doll, PhD and Timothy Kuzel to prepare several manuscripts.
Brian T. Helfand, MD, PhD
Dr. Helfand is an Assistant Professor of Urology at NorthShore University HealthSystem as well as an Adjunct Professor in the Department of Cell & Molecular Biology at Northwestern University. Brian’s main clinical and research interests are focused on the genetics of prostate cancer and urologic diseases. He has recently received a SPORE Career Development Award to study the functional consequences of genetic variations in prostate cancer. Dr. Helfand is a member of the Prostate InterSPORE Genetics Working Group and has participated in SPORE collaborations with deCODE Genetics. He has worked closely with SPORE team members including William Catalona MD; Charles Brendler, MD; Chung Lee, PhD; Qiang Zhang, PhD, Shad Thaxton, MD, PhD, and John Witte, PhD on many SPORE projects.
Borko D. Jovanovic, MS, PhD
Dr. Jovanovic is SPORE biostatistician with research interests in design, analysis and practice of clinical trials, epidemiology, basic science studies and communication of statistical ideas. He is Associate Professor of Preventive Medicine, Feinberg School of Medicine, and divides his time between the NUCATS (Northwestern University Translational Research Institute), where he is a member of the BERD and BCC, and the Robert H. Lurie Comprehensive Cancer Center where he serves on the Scientific Review Committee and on Data Monitoring Committee. In addition, Dr. Jovanovic is principal statistician on the NIH-funded Clinical Trials of Cancer Chemopreventive Agents headed by Dr. Raymond Bergan. This center/subcontract helps create and fund clinical studies that evaluate the cell and molecular effects of chemopreventive agents in humans through the conduct of phase 1 and 2 biomarker based trials, in the context of a multi-institutional consortia.
Karen Kaul, MD, PhD
Dr. Kaul is Board of Directors Chair, Department of Pathology at NorthShore University HealthSystem and also Clinical Professor of Pathology, University of Chicago. In addition to overseeing the collection of biospecimens for the Prostate SPORE, Dr. Kaul is investigating genetic methods to develop new biomarkers for prostate cancer. Dr. Kaul collaborates with most of the SPORE investigators through her role as director of the Biospecimen Pathology Core, including Walter Stadler, MD, Chung Lee, PhD, Jindan Yu, MD, PhD, Piotr Kulesza, MD, Daniel Shevrin, MD, Charles Brendler, MD, Brian Helfand, MD, PhD, and Zhou Wang, PhD.
Stephen J. Kron MD, PhD
Dr. Kron is a Professor of Molecular Genetics and Cell Biology and an Investigator in the Ludwig Center for Metastasis Research at the University of Chicago. His work has explored cellular responses to DNA damage including DNA repair, chromatin modifications, checkpoint signaling and accelerated senescence. Dr. Kron has a translational focus particularly relevant to prostate cancer that is directed at enhancing the effects of radiation therapy by discovery of radiosensitizers, exploiting effects on the microenvironment and promoting activation of anti-tumor immune responses. Dr. Kron works closely with Ralph Weichselbaum, MD, Timothy Kuzel, MD, Walter Stadler and Donald Vander Griend, PhD.
Faculty Profile: http://mgcb.uchicago.edu/faculty/kron/index.html
Timothy Kuzel, MD
Dr. Kuzel is Professor of Medicine and Dermatology, and Director of the Clinical Research Office of the Robert H. Lurie Comprehensive Cancer Center. He has a long-standing interest in the treatment of genitourinary and hematologic cancers with novel biologic therapies and was recently appointed Director of the Walter S. and Lucienne Driskill Immunotherapy Research Program, established with a generous donation of $5 million from the Driskill family, to develop an immunotherapy program at Northwestern University. He also is a member of the Chicago Prostate Cancer Association, an affiliate of the Department of Defense and Prostate Cancer Foundation funded Prostate Cancer Clinical Trials Consortium. Through these activities, Dr. Kuzel collaborates with Walter Stadler, MD, Chung Lee, PhD, Bin Zhang, MD, PhD, Gary MacVicar, MD, Jindan Yu, MD, PhD, Daniel Shevrin, MD and Stephen Kron, MD, PhD.
Faculty Profile: http://fsmweb.northwestern.edu/faculty/facultyProfile.cfm?xid=14960
Chung Lee, PhD
Dr. Lee is Professor Emeritus in the Department of Urology. Dr. Lee served as SPORE PI from 2001 to 2013. His research focus is on the biology of prostate cancer, with a particular focus on TGF-beta signaling and development of immunotherapy for treatment of advanced prostate cancer. Dr. Lee collaborates extensively with SPORE faculty including William Catalona, MD, Raymond Bergan, MD, Susan Crawford, MD, Jennifer Doll, PhD, Paul Lindholm, MD, Charles Brendler, MD, Timothy Kuzel, MD, Jindan Yu, MD, PhD, Bin Zhang, PhD and Zhou Wang, PhD. He also serves as mentor to many junior faculty, including Brian Helfand, MD, PhD, Shilajit Kundu, MD and Joshua Leonard, PhD.
Faculty Profile: http://fsmweb.northwestern.edu/faculty/FacultyProfile.cfm?xid=12272
Robin Leikin, PhD
Dr. Leikin is Scientific Program Director of the Robert H. Lurie Comprehensive Cancer Center and SPORE Scientific Administrator since 2001, responsible for integrating the SPORE projects, cores, developmental research and career development programs. She works closely with the SPORE PI (W. Catalona), Co-PI (W. Stadler) and Grants Administrator (M. Pattison) to manage the day-to-day SPORE Program operations. In this capacity, Dr. Leikin interacts with all SPORE investigators. Dr. Leikin also helps organize interSPORE-sponsored meetings and raises funds for TEAM SPORE participation in the annual US Too Sea Blue Chicago Prostate Cancer walk.
For full bio, see: http://fsmweb.northwestern.edu/faculty/FacultyProfile.cfm?xid=12300
Joshua N. Leonard, PhD
Dr. Leonard is an Assistant Professor of Chemical and Biological Engineering in the McCormick School of Engineering and Applied Science and is a member of the Chemistry of Life Processes Institute at Northwestern University. His research group engineers novel biological systems that perform customized, sophisticated functions for applications in biotechnology and medicine. Dr. Leonard is applying his research to prostate cancer and works closely with his mentors, Chung Lee, PhD and Timothy Kuzel, MD.
Ms. Lewitt is a Senior Grants and Contracts Administrator in the Lurie Cancer Center. She has been a member of the SPORE administrative team since 2013, working closely with Drs. Catalona, Lee, Stadler, and Leikin. Ms. Lewitt is responsible for day-to-day financial and administrative functions of the SPORE.
Kathy A. Mangold, PhD
Dr. Mangold is an investigator of the SPORE in Prostate Cancer, Director of Operations of the NorthShore Biospecimen Repository and Research Scientist in Pathology at NorthShore University HealthSystem, and Clinical Associate Professor of Pathology at the University of Chicago. Dr. Mangold has worked closely with SPORE team members Brian Helfand, MD, PhD; Charles Brendler, MD; and Chung Lee, PhD on SPORE projects and pilot projects.
Andrew Mazar, PhD
Dr. Mazar directs the Center for Developmental Therapeutics (CDT) and its Developmental Therapeutics Core (DTC). CDT scientists are developing a number of new therapeutics that could have utility in treating advanced prostate cancer including a panel of urokinase plasminogen activator (uPA) and its receptor (uPAR)-targeted agents. In addition, CDT investigators are evaluating novel small molecules that target GSK-3. Besides its own programs, CDT and DTC collaborate with a number of prostate cancer SPORE investigators including Ray Bergan, Karl Scheidt, Olga Volpert, Irina Budunova, and C. Shad Thaxton.
Web site: http://www.cdt.northwestern.edu/
Adam B. Murphy, MD, MBA
Dr. Murphy is an Assistant Professor of Urology in the Feinberg School of Medicine. He is a recent recipient of a Career Development Award from the Veteran’s Health Administration as a result of pilot funding from the SPORE. He is mentored by SPORE PI, Dr. Catalona, on his DOD funded study evaluating the role of vitamin D status and related genetic polymorphisms on prostate cancer aggressiveness. He also is investigating the role of HIV status on prostate cancer incidence and on treatment disparities with funding from the NIH Office of AIDS Research. Dr. Murphy has collaborated with Chung Lee, PhD and Rick Kittles, PhD at University of Illinois on SPORE pilot projects and a NIH Diversity supplement.
Faculty Profile: http://fsmweb.northwestern.edu/faculty/facultyProfile.cfm?xid=19570
Thomas O'Halloran, PhD
Dr. O'Halloran is a Professor in the Departments of Chemistry and Molecular Biosciences, the Director of the Chemistry of Life Processes Institute at NU and the Senior Advisor to the Director at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. His research focuses on molecular mechanisms regulating the uptake, trafficking, utilization and intracellular fluxes of metals essential for growth and proliferation, nanoscale drug delivery mechanisms and on the mechanisms of clinically important anticancer agents that are based on arsenic, molybdenum and platinum chemistry. Dr. O'Halloran collaborates with SPORE investigators Andrew Mazar, PhD, Chung Lee, PhD and Gayle Woloschak, PhD.
Faculty Profile: http://www.chemistry.northwestern.edu/faculty/thomas-ohalloran.html
Aytekin Oto, MD
Dr. Oto is Professor of Radiology and Surgery and Chief of Abdominal Imaging and Chief of Body MRI in the University of Chicago. His research interests include MR imaging and image guided therapy of prostate cancer. He works closely with Ralph Weichselbaum, MD and Charles Pelizzari, PhD. on SPORE related research.
Faculty Profile: http://www.uchospitals.edu/physicians/aytekin-oto.html
Charles A. Pelizzari, Ph.D.
Dr. Pelizzari is Associate Professor and Director of Medical Physics in the Department of Radiation and Cellular Oncology at the University of Chicago. His research interests include image guidance for radiotherapy and other cancer treatment modalities. In a SPORE development project together with Dr. Stephen Kron, he is utilizing an image-guided precision small animal radiotherapy system to study the effects of precisely delivered doses of radiation on the tumor microenvironment.
Professional website: http://radonc.sites.uchicago.edu/page/charles-pelizzari-phd
Frank J. Penedo, PhD
Dr. Penedo is the Roswell Park Professor of Medical Social Sciences (MSS) at Northwestern University’s Feinberg School of Medicine. Dr. Penedo is also the Program Leader for the Cancer Control and Survivorship Program of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. His work focuses on evaluating sociocultural, psychosocial and physiological determinants of health related quality of life, symptom burden and physical health outcomes in prostate cancer survivorship. He also studies how in person and technology based psychosocial interventions in multiethnic prostate cancer survivors can improve quality of life and symptom burden in both localized and advanced disease via improved psychosocial and physiological adaptation with an emphasis on endocrine and inflammatory pathways. Dr. Penedo collaborates with SPORE team members David Cella, PhD, David Victorson, PhD and Adam Murphy, MD.
Faculty Profile: http://fsmweb.northwestern.edu/faculty/FacultyProfile.cfm?xid=24719
Website: Cancer Survivorship Institute
Daniel Shevrin, MD
Dr. Shevrin is a Clinical Associate Professor of Medicine at the Pritzker School of Medicine, University of Chicago, and a Senior Attending in the Section of Hematology/Oncology at NorthShore University HealthSystem . He works closely with the SPORE advocates to promote SPORE activities in the community. He is a member of the NCI GU Steering Committee and is Co-PI of the Chicago Prostate Group, which is one of 14 sites in the DOD-funded PCCTC (Prostate Cancer Clinical Trials Consortium). He is Community Co-Chair of the ECOG GU Committee. Dr. Shevrin has worked closely with SPORE team members Timothy Kuzel, MD, Walter Stadler, MD, Gary MacVicar, MD, Zhou Wang, PhD, Raymond Bergan, MD, and Charles Brendler, MD, on SPORE projects.hSystem . He works closely with the SPORE advocates to promote SPORE activities in the community. He is a member of the NCI GU Steering Committee and is Co-PI of the Chicago Prostate Group, which is one of 14 sites in the DOD-funded PCCTC (Prostate Cancer Clinical Trials Consortium). He is Community Co-Chair of the ECOG GU Committee. Dr. Shevrin has worked closely with SPORE team members Timothy Kuzel, MD, Walter Stadler, MD, Gary MacVicar, MD, Zhou Wang, PhD, Raymond Bergan, MD, and Charles Brendler, MD, on SPORE projects.
Clinical Profile: http://www.northshore.org/apps/findadoctor/doctor.aspx?docid=331
Walter Stadler, MD
Dr. Stadler is Fred C. Buffett Professor of Medicine, Chief of the Section of Hematology/Oncology and Deputy Director of the University of Chicago Comprehensive Cancer Center. He serves as SPORE Co-PI, working alongside Dr. Catalona to fulfill the SPORE mission. Dr. Stadler's research focus is on development of novel predictive biomarkers for advanced and metastatic prostate cancer. In addition to treating patients with advanced prostate cancer, he directs the NCI funded University of Chicago Phase II Consortium. Dr. Stadler served as PI of the Chicago Prostate Cancer Association (2009-2014), one of 13 members sponsored by the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium. He has served as mentor for several investigators supported by the Prostate Cancer Foundation and DOD Prostate Cancer Training awards. Dr. Stadler collaborates with Timothy Kuzel, MD, Ralph Weichselbaum, MD, Stephen Kron, MD, PhD, Daniel Shevrin, MD, Donald Vander Griend, PhD, Karen Kaul, MD, PhD, Russell Szmulewitz and Suzanne Conzen.
Faculty Profile: http://www.uchospitals.edu/physicians/walter-stadler.html
Russell Szmulewitz, MD
Dr. Szmulewitz is Assistant Professor in the Department of Medicine at the University of Chicago. He obtained his MD degree from the University of Chicago and completed fellowship training at the same institution following residency at NYU Medical Center. In addition to his clinical research focus on treating men with advanced prostate cancer, Dr. Szmulewitz directs a laboratory that studies prostate cancer progression in animal models and in vitro. He has recently developed a novel technology to isolate and study markers on circulating cells from men with advanced prostate cancer. Dr. Szmulewitz collaborates with SPORE investigators Drs. Suzanne Conzen, Walter Stadler, Donald Vander Griend, Ramana Davuluri and Sarki Abdulkadir.
C. Shad Thaxton, MD, PhD
Dr. Thaxton is an Assistant Professor of Urology in the Feinberg School of Medicine. Dr. Thaxton is a member of the International Institute of Nanotechnology (IIN), and the Institute for BioNanotechnology and Medicine (IBNAM). Dr. Thaxton’s laboratory focuses on the synthesis of therapeutic nanostructures, drug delivery, and lipid metabolism. More specifically, Dr. Thaxton is investigating how synthetic, biomimetic nanostructures can be used to systemically deliver nucleic acid therapies to castrate resistant prostate cancer. Dr. Thaxton’s research is supported by Northwestern’s NCI-funded Center of Cancer Nanotechnology Excellence (CCNE), a Prostate Cancer Foundation (PCF) Innovation Award (PI), and by the National Institutes of Health. Dr. Thaxton is the co-founder of AuraSense and AuraSense Therapeutics, two start-up biotechnology companies poised to more rapidly develop therapeutic nanostructures, potentially ones for advanced prostate cancer. Collaborators include Steve Rohan, MD, Olga Volpert, PhD, Chad Mirkin, PhD, Jindan Yu, MD, PhD and Donald VanderGriend, PhD.
Faculty Profile: http://fsmweb.northwestern.edu/faculty/facultyProfile.cfm?xid=18684
Donald Vander Griend, PhD
Dr. Vander Griend is Assistant Professor of Urology. His research at the University of Chicago focuses on understanding the function of the human prostate as it relates to (1) developmental and stem cell signaling pathways in prostate homeostasis and disease initiation, (2) dependence upon androgen and the supporting stroma, and (3) molecular events driving BPH and prostate carcinogenesis. Dr. Vander Griend collaborates with Karen Kaul, MD, PhD, Stephen Kron, MD, PhD, Walter Stadler, MD, C. Shad Thaxton, MD, PhD, Ralph Weichselbaum, MD and Jindan Yu, MD, PhD.Faculty Profile: http://biomed.uchicago.edu/common/faculty/vander_griend.html
David Victorson, PhD
Dr. Victorson is an Assistant Professor of Medical Social Sciences in the Feinberg School of Medicine and Director of Research at Northwestern Integrative Medicine at Northwestern Memorial Hospital. Dr. Victorson oversees several prostate cancer focused observational and clinical trials dealing with health-related quality of life measurement, use of integrative oncology to manage fear of cancer progression among men on active surveillance and their spouses, and the application of eHealth tools for symptom management support following definitive therapy. Dr. Victorson has worked closely with SPORE team members Frank Penedo, PhD; Brian Helfand, MD, PhD; Charles Brendler, MD; and Chung Lee, PhD on prostate cancer studies.
Faculty Profile: http://www.mss.northwestern.edu/faculty/Victorson.html
Zhou Wang, Ph.D.
Dr. Wang is Professor and Director of Urological Research in the Department of Urology, University of Pittsburgh School of Medicine and Co-Leader of the Prostate Cancer Program (PCP). His research focuses on androgen action and prostate cancer with a goal of developing new targets for treatment of BPH and prostate cancer. Dr. Wang's laboratory research is supported by the NIH. He is also PI of a P20 University of Pittsburgh Planning Center for Interdisciplinary Research in Benign Urology (IR-BU) and PI of a T32 NIDDK-funded Urologic Training Program for Scientists. He has worked closely with SPORE team members Daniel Shevrin, MD; Ximing Yang; MD, PhD; Karen Kaul, MD, PhD; Borko Jovanovic, PhD and William Catalona, MD on SPORE projects and pilot projects.
Dr. Ralph Weichselbaum
The Daniel K Ludwig Professor and Chairman of the Department of Radiation and head of the Ludwig Center for Metastasis Research at The University of Chicago is the CO-PI of a current SPORE project on radio inducible gene therapy and the relationship of interferon stimulated genes to resistance to DNA damaging agents. Dr. Weichselbaum has worked closely with SPORE team members Dr. Walter Stadler and Dr. Stan Liauw and with Dr. Steven Kron on a new senescent tumor vaccine. Dr. Weichselbaum is a member of the Institute of Medicine and is on the National Cancer Policy Board.
Faculty Profile: http://www.uchospitals.edu/physicians/ralph-weichselbaum.html
Laboratory Profile: http://ludwigcenter.sites.uchicago.edu
Jian-Jun Wei, MD
Jian-Jun Wei, MD is a Surgical Pathologist at (NMH), Professor of Pathology, and Director of the Pathology Core Facility of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. Wei completed residency and fellowship training at New York University School of Medicine and is board certified in Anatomic Pathology and Clinical Pathology. As Director of the Pathology Core Facility and co-director of the Biospecimen Pathology Core, Dr. Wei serves as liaison between the SPORE and the Pathology Core Facility to ensure that the two core facilities operate optimally and do not duplicate resources and services. He works with Dr. Yang to support SPORE projects with respect to their biospecimen, pathology and immunohistochemistry needs. Dr. Weiâ€™s major research interests are on identification of molecular biomarkers that are associated with tumor growth and progression.
Faculty Profile: https://fsmweb.northwestern.edu/faculty/FacultyProfile.cfm?xid=18474
Gayle E. Woloschak, PhD
Dr. Woloschak is Professor of Radiation Oncology, Radiology, and Cell and Molecular Biology, Associate Director of the Radiation Oncology Residency Program, and active in the Robert H. Lurie Cancer Center and the NCI-funded Center for Nanotechnology Excellence (CCNE). She also serves as PI of an NCI-funded R25 in Cancer and Nanotechnology in Imaging and Radiotherapy. Her scientific interests are predominantly in the areas of Radiation Biology and Nanotechnology studies, and she has authored over 160 scientific papers. She has grants from the National Institutes of Health and the Department of Energy.
Woloschak is Professor of Radiation Oncology, Radiology, and Cell and Molecular Biology, Associate Director of the Radiation Oncology Residency Program, and active in the Robert H. Lurie Cancer Center and the NCI-funded Center for Nanotechnology Excellence (CCNE). She also serves as PI of an NCI-funded R25 in Cancer and Nanotechnology in Imaging and Radiotherapy. Her scientific interests are predominantly in the areas of Radiation Biology and Nanotechnology studies, and she has authored over 160 scientific papers. She has grants from the National Institutes of Health and the Department of Energy.
Jianfeng Xu, MD, DrPH
Dr. Xu was recently recruited from Wake Forest University School of Medicine to NorthShore University HealthSystem to become the new Vice President of Translational Research. Dr. Xu obtained his MD from Shanghai Medical University and his doctorate of public health in genetic epidemiology from Johns Hopkins University. His primary research interests are 1) discovery of inherited and somatic genetic alterations that are associated with development and progression of prostate cancer, and 2) translation of genomic findings for targeted prevention, screening, and treatment of prostate cancer. Dr. Xu collaborates with SPORE investigators Drs. Charles Brendler, William Catalona, Brian Helfand and Karen Kaul.
Ximing Yang, MD, PhD
Dr. Yang is Professor in the Department of Pathology at Northwestern University. He is an expert prostate pathologist who has supported the SPORE's specimen needs for over 10 years. Dr. Yang contributes to the quality control of the SPORE specimen bank and works closely with Karen Kaul, MD, PhD and Piotr Kulesza, MD, PhD to review and guide specimen requests.
Faculty Profile: http://www.pathology.northwestern.edu/Faculty/FacultyBio.cfm?ID=34
Faculty Profile: http://fsmweb.northwestern.edu/faculty/FacultyProfile.cfm?xid=17338
Jindan Yu, MD, PhD
Dr. Yu is an Assistant Professor of Hematology/Oncology, Department of Medicine in the Feinberg School of Medicine. Dr. Yu was previously trained in the laboratory of Dr. Arul M. Chinnaiyan, the PI of the prostate cancer SPORE of the University of Michigan. While there, she collaborated and published together with members of Michigan SPORE including Drs. Ken Pienta and Rajal Shah. At Northwestern University, Dr. Yu is actively engaged in the Prostate SPORE and has collaborated or is in collaboration with SPORE team members including Drs. Chung Lee, Raymond Bergan, Timothy Kuzel, Ximing Yang, Shad Thaxton, Olga Volpert, Don Vander Griend, Gary MacVicar, and William Catalona. She also has pilot funding through the Northwestern NCI-funded Physical Sciences and Oncology (PSOC) grant. Dr Yu's research is been supported by the NIH, American Cancer Society (ACS) and the Department of Defense (DOD).
Faculty profile: http://fsmweb.northwestern.edu/faculty/facultyProfile.cfm?xid=18755
Lab website: http://www.yulab.northwestern.edu/
Bin Zhang, MD; PhD
Dr. Zhang is Associate Professor of Medicine, Division of Hematology and Oncology in the Feinberg School of Medicine. Dr. Zhang's research focuses on the interactions between cancer cells and immune system in the tumor microenvironment and development of novel cancer immunotherapeutics. Dr. Zhang works closely with SPORE team members Timothy Kuzel, MD and Chung Lee, PhD on SPORE projects.
Faculty Profile: http://fsmweb.northwestern.edu/faculty/FacultyProfile.cfm?xid=25431